BOSTON / Feb 20, 2024 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2023 before market open on Tuesday, March 5, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.
Last Trade: | US$2.39 |
Daily Change: | 0.01 0.42 |
Daily Volume: | 414,703 |
Market Cap: | US$82.840M |
November 12, 2024 August 06, 2024 April 30, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB